Saxagliptin (Onglyza) indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin and a sulfonylurea when dual therapy with these two agents, with diet and exercise, does not provide adequate glycemic control

Saxagliptin (Onglyza) is an oral antihyperglycemic agent belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Saxagliptin is indicated for patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a sulfonylurea, metformin and a sulfonylurea, or lo...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2013, 2013
Series:Common drug review clinical review report
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:Saxagliptin (Onglyza) is an oral antihyperglycemic agent belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Saxagliptin is indicated for patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a sulfonylurea, metformin and a sulfonylurea, or long- or intermediate-acting insulin (with or without metformin), when these drugs do not provide adequate glycemic control. The recommended dose of saxagliptin is 5 mg once daily for most patients and 2.5 mg once daily for patients with moderate or severe renal impairment (creatinine clearance [CrCl] d 50 mL/min). The current Common Drug Review (CDR) submission for saxagliptin is for the manufacturer's requested listed criterion of use in combination with metformin and a sulfonylurea for patients with inadequate glycemic control and for whom insulin is not an option
Item Description:Title from Web page
Physical Description:1 online resource illustrations